• Je něco špatně v tomto záznamu ?

Efficacy and Safety of Stereotactic Radiotherapy in Patients With Recurrent Ventricular Tachycardias: The Czech Experience

J. Hašková, D. Wichterle, J. Kautzner, M. Šramko, P. Peichl, L. Knybel PEng, O. Jiravský, R. Neuwirth, J. Cvek

. 2024 ; 10 (4) : 654-666. [pub] 20240221

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014468

BACKGROUND: Stereotactic arrhythmia radiotherapy (STAR) has been proposed recently in patients with refractory ventricular tachycardia (VT). OBJECTIVES: The purpose of this study was to describe the efficacy and safety of STAR in the Czech Republic. METHODS: VT patients were recruited in 2 expert centers after at least 1 previously failed catheter ablation (CA). A precise strategy of target volume determination and CA was used in 17 patients treated from December 2018 until June 2022 (EFFICACY cohort). This group, together with an earlier series of 19 patients with less-defined treatment strategies, composed the SAFETY cohort (n = 36). A dose of 25 Gy was delivered. RESULTS: In the EFFICACY cohort, the burden of implantable cardioverter-defibrillator therapies decreased, and this drop reached significance for direct current shocks (1.9 ± 3.2 vs 0.1 ± 0.2 per month; P = 0.03). Eight patients (47%) underwent repeated CA for recurrences of VT during 13.7 ± 11.6 months. In the SAFETY cohort (32 procedures, follow-up >6 months), 8 patients (25%) presented with a progression of mitral valve regurgitation, and 3 (9%) required intervention (median follow-up of 33.5 months). Two cases of esophagitis (6%) were seen with 1 death caused by the esophago-pericardial fistula (3%). A total of 18 patients (50%) died during the median follow-up of 26.9 months. CONCLUSIONS: Although STAR may not be very effective in preventing VT recurrences after failed CA in an expert center, it can still modify the arrhythmogenic substrate, and when used with additional CA, reduce the number of implantable cardioverter-defibrillator shocks. Potentially serious sides effects require close follow-up.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014468
003      
CZ-PrNML
005      
20240905134321.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacep.2023.12.002 $2 doi
035    __
$a (PubMed)38385912
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hašková, Jana $u Department of Cardiology, IKEM, Prague, Czech Republic; Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. Electronic address: hasj@ikem.cz
245    10
$a Efficacy and Safety of Stereotactic Radiotherapy in Patients With Recurrent Ventricular Tachycardias: The Czech Experience / $c J. Hašková, D. Wichterle, J. Kautzner, M. Šramko, P. Peichl, L. Knybel PEng, O. Jiravský, R. Neuwirth, J. Cvek
520    9_
$a BACKGROUND: Stereotactic arrhythmia radiotherapy (STAR) has been proposed recently in patients with refractory ventricular tachycardia (VT). OBJECTIVES: The purpose of this study was to describe the efficacy and safety of STAR in the Czech Republic. METHODS: VT patients were recruited in 2 expert centers after at least 1 previously failed catheter ablation (CA). A precise strategy of target volume determination and CA was used in 17 patients treated from December 2018 until June 2022 (EFFICACY cohort). This group, together with an earlier series of 19 patients with less-defined treatment strategies, composed the SAFETY cohort (n = 36). A dose of 25 Gy was delivered. RESULTS: In the EFFICACY cohort, the burden of implantable cardioverter-defibrillator therapies decreased, and this drop reached significance for direct current shocks (1.9 ± 3.2 vs 0.1 ± 0.2 per month; P = 0.03). Eight patients (47%) underwent repeated CA for recurrences of VT during 13.7 ± 11.6 months. In the SAFETY cohort (32 procedures, follow-up >6 months), 8 patients (25%) presented with a progression of mitral valve regurgitation, and 3 (9%) required intervention (median follow-up of 33.5 months). Two cases of esophagitis (6%) were seen with 1 death caused by the esophago-pericardial fistula (3%). A total of 18 patients (50%) died during the median follow-up of 26.9 months. CONCLUSIONS: Although STAR may not be very effective in preventing VT recurrences after failed CA in an expert center, it can still modify the arrhythmogenic substrate, and when used with additional CA, reduce the number of implantable cardioverter-defibrillator shocks. Potentially serious sides effects require close follow-up.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a komorová tachykardie $x chirurgie $7 D017180
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a radiochirurgie $x škodlivé účinky $x metody $7 D016634
650    _2
$a recidiva $7 D012008
650    _2
$a defibrilátory implantabilní $7 D017147
650    _2
$a katetrizační ablace $x škodlivé účinky $7 D017115
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Wichterle, Dan $u Department of Cardiology, IKEM, Prague, Czech Republic; Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kautzner, Josef $u Department of Cardiology, IKEM, Prague, Czech Republic; Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
700    1_
$a Šramko, Marek $u Department of Cardiology, IKEM, Prague, Czech Republic
700    1_
$a Peichl, Petr $u Department of Cardiology, IKEM, Prague, Czech Republic
700    1_
$a Knybel PEng, Lukáš $u Department of Oncology, University Hospital Ostrava and Ostrava University Medical School, Ostrava, Czech Republic
700    1_
$a Jiravský, Otakar $u Department of Cardiology, Hospital AGEL Třinec-Podlesí, Třinec, Czech Republic; Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Neuwirth, Radek $u Department of Cardiology, Hospital AGEL Třinec-Podlesí, Třinec, Czech Republic; Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Cvek, Jakub $u Department of Oncology, University Hospital Ostrava and Ostrava University Medical School, Ostrava, Czech Republic
773    0_
$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 10, č. 4 (2024), s. 654-666
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38385912 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134315 $b ABA008
999    __
$a ok $b bmc $g 2143927 $s 1226334
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 4 $d 654-666 $e 20240221 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace